Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.61 - $0.98 $17,154 - $27,559
28,122 New
28,122 $20,000
Q3 2022

Nov 14, 2022

BUY
$2.97 - $23.6 $31,636 - $251,387
10,652 Added 44.3%
34,699 $97,000
Q2 2022

Aug 15, 2022

BUY
$2.81 - $5.5 $67,572 - $132,258
24,047 New
24,047 $88,000
Q3 2021

Nov 15, 2021

SELL
$3.23 - $24.73 $92,982 - $711,902
-28,787 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.72 - $3.8 $41,640 - $58,174
15,309 Added 113.59%
28,787 $98,000
Q1 2021

May 17, 2021

BUY
$3.01 - $5.35 $258 - $460
86 Added 0.64%
13,478 $46,000
Q4 2020

Feb 16, 2021

BUY
$1.5 - $3.64 $20,088 - $48,746
13,392 New
13,392 $42,000

Others Institutions Holding NURO

# of Institutions
1
Shares Held
320
Call Options Held
0
Put Options Held
0

About NeuroMetrix, Inc.


  • Ticker NURO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 7,757,230
  • Market Cap $30.1M
  • Description
  • NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to e...
More about NURO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.